These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2669100)

  • 21. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam.
    Trach DD; Clemens JD; Ke NT; Thuy HT; Son ND; Canh DG; Hang PV; Rao MR
    Lancet; 1997 Jan; 349(9047):231-5. PubMed ID: 9014909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
    Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
    J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
    [No Abstract]   [Full Text] [Related]  

  • 24. Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates.
    Kaper JB; Lockman H; Baldini MM; Levine MM
    Nature; 1984 Apr 12-18; 308(5960):655-8. PubMed ID: 6324005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD103-HgR.
    Favre D; Struck MM; Cryz SJ; Viret JF
    Vaccine; 1996 Apr; 14(6):526-31. PubMed ID: 8782351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Live oral vaccines against cholera: an update.
    Levine MM; Kaper JB
    Vaccine; 1993; 11(2):207-12. PubMed ID: 8438619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.
    Levine MM; Kaper JB; Herrington D; Ketley J; Losonsky G; Tacket CO; Tall B; Cryz S
    Lancet; 1988 Aug; 2(8609):467-70. PubMed ID: 2900401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
    Cryz SJ; Fürer E; Germanier R
    Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of a detection system for wild-type Vibrio cholerae in genetically modified cholera vaccine.
    Studer E; Candrian U
    Biologicals; 2000 Sep; 28(3):149-54. PubMed ID: 10964441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.
    Coster TS; Killeen KP; Waldor MK; Beattie DT; Spriggs DR; Kenner JR; Trofa A; Sadoff JC; Mekalanos JJ; Taylor DN
    Lancet; 1995 Apr; 345(8955):949-52. PubMed ID: 7715293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of cholera and rise of novel mucosal vaccine.
    Yamamoto T
    Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The current status of research on a cholera vaccine].
    Fournier JM
    Bull Soc Pathol Exot; 1998; 91(5 Pt 1-2):412-5. PubMed ID: 10078377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal and systemic immune responses to
    Naidu A; Lulu S S
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1307-1318. PubMed ID: 36255170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with registered mucosal vaccines.
    Dietrich G; Griot-Wenk M; Metcalfe IC; Lang AB; Viret JF
    Vaccine; 2003 Jan; 21(7-8):678-83. PubMed ID: 12531339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.